American journal of respiratory and critical care medicine
The most recent articles from:
Am. J. Respir. Crit. Care Med.
-
Am. J. Respir. Crit. Care Med. · May 2024
Editorial CommentBEACON: A Missing Piece of the Puzzle for COPD.
-
Am. J. Respir. Crit. Care Med. · May 2024
Randomized Controlled Trial Multicenter StudyZinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial.
Rationale: A phase II trial reported clinical benefit over 28 weeks in patients with idiopathic pulmonary fibrosis (IPF) who received zinpentraxin alfa. Objectives: To investigate the efficacy and safety of zinpentraxin alfa in patients with IPF in a phase III trial. Methods: This 52-week phase III, double-blind, placebo-controlled, pivotal trial was conducted at 275 sites in 29 countries. ⋯ Conclusions: Zinpentraxin alfa treatment did not benefit patients with IPF over placebo. Learnings from this program may help improve decision making around trials in IPF. Clinical trial registered with www.clinicaltrials.gov (NCT04552899).